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Background: Expression of programmed cell death ligand 1 (PD-L1) is an important process by which tumor cells
suppress antitumor immunity in the tumor microenvironment. Bone marrow (BM)–derived immune cells are an
important component of the tumor microenvironment. However, the link between PD-L1 induction on tumor cells
and communication with BM cells is unknown.
Results: This study demonstrates that BM cells have a direct effect in inducing PD-L1 expression on tumor cells,
which contributes to the tumor cells’ drug resistance. This novel discovery was revealed using a co-incubation
system with BM cells and tumor cells. BM cells from wild-type C57BL6 mice and the immune-deficient mouse
strains B-cell−/−, CD28−/−, perforin−/−, and Rag2−/− but not CD11b−/− dramatically increased the expression of tumor
cell surface PD-L1. This PD-L1 induction was dependent on CD11b-positive BM cells through direct contact with
tumor cells. Furthermore, p38 signaling was activated in tumor cells after co-incubation with BM cells, whereas the
expression of PD-L1 was remarkably decreased after co-culture of cells treated with a p38 inhibitor. The increase in
PD-L1 induced by BM cell co-culture protected tumor cells from drug-induced apoptosis.
Conclusions: PD-L1 expression is increased on tumor cells by direct contact with BM-derived CD11b-positive cells
through the p38 signaling pathway. PD-L1 may play an important role in drug resistance, which often causes failure
of the antitumor response.
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Chemotherapy resistanceBackground
The tumor microenvironment is comprised of tumor
cells and a variety of other cells including stem, stromal,
and endothelial, and a wide range of immune cells [1].
Many of these nonmalignant cells are derived from bone
marrow (BM) and are recruited by tumor cells to
enhance their survival as well as primary tumor growth,
invasion, and dissemination to distant organs [2]. More-
over, distinct BM-derived populations such as myeloid
cell–derived suppressor cells [3-5], mesenchymal stem
cells [6-8], and tumor-associated macrophages [9,10]* Correspondence: Sli4@mdanderson.org
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unless otherwise stated.have been shown not only to promote cancer cell metas-
tasis but also to escape tumor immune surveillance
through suppression of antitumor T-cell responses.
Although several recent studies have found correlations
between infiltration of particular immune cells into
primary tumors and prognosis in cancer patients
[9,11,12], the details of the mechanism by which BM-
derived cells in the tumor microenvironment contribute
to tumor progression and metastasis have not been fully
established.
Programmed cell death 1 ligand 1 (PD-L1; also known
as B7-H1 or CD274), a 40-kDa transmembrane protein
belonging to the B7 family that negatively regulates
T-cell signaling, is frequently upregulated in a number
of different tumors, including melanoma, ovarian, lung,is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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PD-L1 expression on tumor cells may correlate with
higher malignant grade of tumors and tumor growth
[18]. Also, PD-L1 transmits immune-inhibitory signals
through the programed cell death 1 (PD-1) receptor on
T cells, which allows tumors to escape from immune
surveillance [19].
Several studies have reported the mechanisms of
regulation of PD-L1 on tumor cells. The release of in-
flammatory cytokines such as interferon-gamma (IFN-γ)
activates the signal transducer and activator of transcrip-
tion 3 (STAT3) pathway and subsequently upregulates
PD-L1 expression on lymphoma and lung cancer cells
[20]. It has been also reported that the MyD88/mitogen-
activated protein kinase (MAPK) kinase/extracellular
signal–regulated kinase (MyD88/MEK/ERK) pathway
upregulates PD-L1 transcription, which is initiated by
both IFN-γ and Toll-like receptor ligands, and activates
nuclear factor–kappa B for PD-L1 transcription [21,22].
Additionally, the loss of phosphatase and tensin homo-
log (PTEN) activates the phosphatidylinositide 3-kinase/
Akt (PI3K/Akt) and mammalian target of rapamycin
(mTOR) pathways, which leads to upregulation of PD-
L1 on glioma and breast cancer cells [23,24]. Recently, it
has been shown that tumor cell surface PD-L1 ex-
pression is upregulated by activation of CD8+ T cells in
the melanoma tumor microenvironment [25] and that
microRNA miR-513 repressed the translation of PD-L1,
whereas IFN-γ treatment decreased miR-513 expression
and induced PD-L1 translation [26]. Thus, regulation of
PD-L1 appears to result from complex interactions
between environmental stimuli, intracellular signaling
pathways, and both transcriptional and translational
control mechanisms. However, little is known about the
influence of tumor microenvironment on regulation of
tumor cell surface PD-L1 expression.
In this study, we hypothesized that BM-derived cells
in the tumor microenvironment may interact with
tumor cells and induce tumor cell surface PD-L1 ex-
pression through cell-cell communication. We further
hypothesized that the increased PD-L1 expression may
protect tumor cells from chemotherapeutic drug treat-
ment via increasing drug resistance of tumor cells.
These results showed that PD-L1 expression on tumor
cells was dramatically induced by direct interaction
between BM cells and tumor cells. Notably, CD11b ex-
pression on BM cells was critical for PD-L1 expression
on tumor cells. We also investigated the signaling
mechanism leading to PD-L1 upregulation and demon-
strated that the p38 pathway was involved. Together,
these results reveal a previously undisclosed role for BM
cells in inducing tumor cell surface PD-L1 expression
and implicate the CD11b-positive BM cell population in
this induction.Results
Bone marrow cells induce PD-L1 expression on the tumor
cell surface
PD-L1 expression on tumor cells limits T-cell activation,
attenuates tumor immunosurveillance, and correlates
with tumor growth and metastasis [18,19]. However, the
effect of stromal cells in the tumor microenvironment
on this PD-L1 expression has not been determined. This
investigation focused, therefore, on the regulatory effect
of the BM-derived stromal cells that often surround tu-
mors on expression of PD-L1 on the tumor cell surface.
The co-culturing of B16F10 mouse melanoma cells with
freshly-isolated syngeneic BM cells from C57BL6 mice
allowed for characterization of the contribution of BM
cells in the tumor microenvironment. After 48 hours,
tumor cell surface PD-L1 expression was dramatically
induced by co-culture with these wild-type BM cells
(Figure 1A). Importantly, BM-induced PD-L1 expression
was detected in various other tumor cell lines, including
osteosarcoma and breast cancer cells (Figure 1A and
Additional file 1: Figure S1), which suggests BM-derived
cell–induced PD-L1 expression on tumor cells is a ge-
neral phenomenon and is not cell type specific. To in-
vestigate whether this induction of PD-L1 expression
occurred throughout tumor cells or only on the cell sur-
face, both intracellular and cell surface PD-L1 expression
levels were determined in B16F10 cells by flow cytome-
try. The data show that total PD-L1 levels as well as
surface expression were increased in the B16F10 mela-
noma cells (Figure 1B). Immunocytochemical staining
and confocal microscopy of tumor cells confirmed the
PD-L1 expression in B16F10 cells after co-culture
with BM cells. PD-L1 expression was significantly
greater in co-cultured B16F10 tumor cells than in the
mono-cultured control B16F10 cells (Figure 1C). Taken
together, these results suggest that BM cells induced
PD-L1 expression within the tumor cells and then the
induced PD-L1 translocated to the tumor cell surface.
Western blot and qRT-PCR analysis showed that both
PD-L1 protein and mRNA levels were increased in
B16F10 cells after co-culture with BM cells (Figure 1D
and E), further supporting the suggestion that BM cells
upregulate PD-L1 gene expression.
Direct contact between tumor and bone marrow cells is
required for PD-L1 expression
To investigate whether induction of PD-L1 expression
by BM cells is mediated by direct cell-to-cell contact or
by soluble factors, we conducted an in vitro indirect co-
culture experiment using the ThinCert™ transwell mem-
brane. This membrane kept the two cell populations
physically separated at all stages of the co-culture, while
the pores of the membrane allowed the exchange of
soluble factors between the two compartments. Unlike
Figure 1 Bone marrow cells induce PD-L1 expression on tumor cells. (A) Tumor cell surface PD-L1 expression after co-culture with BM cells
for 48 hours. Cells were stained with isotype control or PE-PD-L1 antibody. PD-L1 expression level was determined by flow cytometry. Data are
presented as mean ± standard error (n = 3), *P <0.05 versus B16F10 alone. Student t test (B) Intracellular PD-L1 in B16F10 cells was detected by
staining with isotype control or PE-PD-L1 antibody, and PD-L1 expression level was examined using flow cytometry. Results are representative of
three independent experiments. (C) Immunostaining of PD-L1 (red) expression in B16F10 cells in monoculture or co-culture with BM cells. Nucleus
(blue) was stained with DRAQ5. (D) Total RNA was isolated from B16F10 cells co-cultured with BM cells and then subjected to qRT-PCR to measure the
level of PD-L1. As a control, mono-cultured B16F10 cells and BM cells were separately collected using Trizol and then followed total RNA isolation to
measure the level of PD-L1. The levels of GAPDH were also determined and served as an internal control for standardization. Data are presented as
mean ± standard error (n = 3), *P <0.05 versus control. (E) B16F10 cells were co-cultured with BM cells for 48 hours and subjected to lysis; cell lysates
were subjected to immunoblotting to detect PD-L1. β-actin was used as a loading control. MFI = Median Fluorescence Intensity, BM = Bone Marrow.
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BM cells did not induce PD-L1 expression on the tumor
cell surface (Figure 2A and B). This result was further
confirmed using DBT cells (Additional file 1: Figure S2).
Taken together, tumor cells require direct contact to
communicate with BM cells to induce surface PD-L1
expression.
PD-L1 upregulation is dependent on CD11b-expressing
BM cells in the tumor microenvironment
To identify which BM subpopulation is responsible for
PD-L1 expression on tumor cells, BM cells from diffe-
rent knockout mice deficient in CD28, perforin, B cells,
Rag2, or CD11b were isolated and co-incubated with
B16F10 cells. After 48 hours, tumor cell surface PD-L1
expression was examined using flow cytometry. All of
the BM cells from different knockout mice retained the
capacity to induce surface PD-L1 expression in B16F10
cells (Figure 3A, C, D and E) except those deficient in
CD11b (Figure 3B). These data show that tumor cells
may regulate PD-L1 expression on tumor cells via com-
munication with CD11b-positive BM cells in the tumor
microenvironment and that CD28-positive cells, natural
killer cells, B cells, and T cells are not critical for induc-
tion of tumor cell surface PD-L1 expression. To confirm
the role of CD11b in the communication between tumor
and BM cells, CD11b-neutralizing antibodies were added
during the co-culture with BM cells, leading to sig-
nificantly lower PD-L1 expression on the tumor cells
(Figure 3F). The importance of CD11b in PD-L1 in-
duction on B16F10 cells was further confirmed by co-
culture with CD11b-positive BM cells separated from
the mixed BM cells, showing PD-L1 induction on theFigure 2 Direct interaction between BM and tumor cells is required fo
B16F10 cells in monoculture or co-culture with BM cells by staining with isoty
with (A) Bar Graph, (B) Histogram. Data are presented as mean ± standard err
Fluorescence Intensity, BM= Bone Marrow.tumor cells similar to co-culturing with total BM cells
(Figure 3G). Taken together, these results indicate that
CD11b-expressing BM cells communicate with tumor
cells in the tumor microenvironment to induce tumor
cell surface PD-L1 expression.
Bone marrow cells induce PD-L1 expression on tumor
cells in a p38 pathway–dependent manner
Next, we looked into the molecular pathways regulating
induction of tumor cell surface PD-L1 expression by BM
cells. Several signaling pathways, including the STAT3,
MAPK, and PI3K pathways, have been shown to regulate
PD-L1 expression on cancer cells [20-24]. Thus, the acti-
vation of signaling components, including ERK, JNK,
p38, AKT, mTOR, p70-S6K, and STATs, was examined
via intracellular staining and flow cytometry in B16F10
cells after 48 hours of co-culture with BM cells. Al-
though the STAT3 signaling pathway has been reported
to regulate PD-L1 expression in the NPM/ALK-carrying
T cell lymphoma (ALK + TCL) cells [20], BM cell inter-
action did not activate STAT3 in B16F10 tumor cells. In
the western blot data, both BM and the mixture of
B16F10 tumor cells plus BM cells showed the activated
STAT3 (pSTAT3), but it is not possible to determine
whether the pSTAT3 expression is from the tumor cells
or BM cells (Additional file 1: Figure S3). Flow cytome-
try analysis clearly showed that pSTAT3 activation in
co-cultured B16F10 cells was not increased compared to
monocultured B16F10 cells (Figure 4A). The activation
of p38 in tumor cells was markedly increased compared
to that of the others after BM cell co-culture (Figure 4A).
The increased expression of p-p38 protein was con-
firmed by western blotting (Figure 4B). To test whetherr PD-L1 expression. Cell surface PD-L1 expression was detected on
pe control or PD-L1 antibody and flow cytometry. Data was represented
or (n = 3). *P <0.05 versus B16F10 alone, student t test. MFI = Median
Figure 3 CD11b-positive BM cells are critical for PD-L1 expression. B16F10 tumor cell surface PD-L1 expression was determined after co-culture
with BM cells isolated from knockout mice, including (A) B−/−, (B) CD11b−/−, (C) CD28−/−, (D) Rag2−/−, and (E) perforin−/−mice. (F) B16F10 cells
were pre-incubated with anti-rat-IgG or CD11b-neutralizing antibody and co-cultured with BM cells. PD-L1 expression was determined by staining
with isotype control or PE/Cy7-PD-L1 antibody and using flow cytometry. (G) CD11b-positive BM cells were separated from the mixed BM cells using
PE-CD11b-coupled nanoparticles. B16F10 cells were co-cultured with CD11b-positive BM cells for 48 hours and then stained with isotype control or
PE/Cy7-PD-L1 antibody. PD-L1 expression level was determined by flow cytometry. Data are presented as mean ± standard error (n = 3), *P <0.05 versus
B16F10 alone, student t test. MFI =Median Fluorescence Intensity, BM= Bone Marrow.
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Figure 4 Induction of PD-L1 by BM cells is dependent on the p38 signaling pathway. (A) B16F10 cells co-cultured with BM cells were
stained with pERK, pJNK, pp38, pAKT, pmTOR, pp70-S6K, pSTAT1, pSTAT3 pSTAT4, and pSTAT5 antibodies and analyzed using flow cytometry. Fold
increase represents the MFI ratio between co-culture and monoculture (MFI of B16F10 in co-culture/MFI of B16F10 in monoculture). (B) B16F10
cells co-cultured with BM cells were subjected to lysis, and cell lysates were subjected to immunoblotting to detect PD-L1 and p-p38 levels.
β-actin was used as a loading control. (C) PD-L1 expression was determined in B16F10 cells co-cultured with BM cells and p38 inhibitor
PH797804 by staining with PD-L1 antibody and flow cytometry analysis. (D) B16F10 cells were treated with 1 μM PH797804 during co-culture
with BM cells for 48 hours. Cells were subjected to lysis, and cell lysates were subjected to immunoblotting to detect PD-L1. β-actin was used as
a loading control. (E) B16F10 cells were treated with 5 μM PH797804 during monoculture or co-culture with BM cells for 48 hours and then
stained with annexin V and PI to determine cell viability by flow cytometry. Data are presented as mean ± standard error (n = 3). *P <0.05 versus
B16F10 alone, student t test. MFI = Median Fluorescence Intensity, BM = Bone Marrow.
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upregulation, we added a p38-specific inhibitor, PH797804,
to the co-cultures and determined its effect on PD-L1 ex-
pression on B16F10 cells. This inhibitor abrogated BM
cell–induced PD-L1 expression on B16F10 cells in a dose-
dependent manner (Figure 4C). The suppression of PD-L1
expression by PH797804 was confirmed by western blot-
ting (Figure 4D). Additionally, the B16F10 cells were still
viable after the treatment of 5 μM PH797804 (Figure 4E).
These data show that integral activation of p38 is required
for the BM cell induction of PD-L1 expression on B16F10
tumor cells.Bone marrow cells protect tumor cells and increase drug
resistance via upregulation of PD-L1 expression
A recent study showed that high PD-L1–expressing
basal type breast cancer cell lines overexpress genes in-
volved in chemoresistance compared to low PD-L1–ex-
pressing breast cancer cell lines [27]. So, it is possible
that overexpression of PD-L1 on the tumor cell surface
may be a mechanism whereby BM cells protect tumor
cells from drug treatment. To test this hypothesis,
B16F10 cells were treated with gemcitabine (1 μM or
100 μM) during monoculture or co-culture with BM
cells. After 48 hours, the B16F10 cells were analyzed
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drug-induced apoptosis. The proportion of viable cells
was higher in co-cultured gemcitabine-treated B16F10
cells than in mono-cultured treated B16F10 cells,
whereas the proportions of apoptotic and necrotic cells
in co-cultured gemcitabine-treated B16F10 cells were
decreased (Figure 5A). This result indicates that BM-
derived immune cells in the tumor microenvironment
protect tumor cells from drug treatment. To investigate
the role of tumor cell surface PD-L1 in the response
to drug treatment, B16F10 cells were incubated with
PD-L1 blocking antibodies (concentration at 2 μg/mL)
prior to adding BM cells. B16F10 cells in which PD-L1Figure 5 BM cells increase drug resistance of tumor cells and protect
gemcitabine during co-culture with BM cells for 48 hours and then stained w
cells by flow cytometry. (B) B16F10 cells were pre-incubated with PD-L1–bloc
co-culture with BM cells. Proportions of necrotic and apoptotic cells were det
100 μM gemcitabine during co-culture with BM cells for 48 hours. Proportion
presented as mean ± standard error (n = 3). BM= Bone Marrow, GEM = Gemcwas blocked with PD-L1 antibodies were then co-
cultured with BM cells and gemcitabine for 48 hours.
Pacific blue–annexin V and PI staining showed that
apoptosis and necrosis of B16F10 cells that had been
inhibited by BM cells were increased by blocking PD-L1
after treatment with gemcitabine (Figure 5B), indicating
the anti-apoptotic role of PD-L1 in tumor cells. Ad-
ditionally, the role of p38 in the PD-L1 mediated drug
resistance was further confirmed by the treatment of
5 μM PH797804 and 100 μM gemcitabine during co-
culture with BM cells for 48 hrs. The proportion of
viable cells was lower in co-cultured PH797804 and
gemcitabine-treated B16F10 cells than in co-culturedthem via upregulation of PD-L1. (A) B16F10 cells were treated with
ith annexin V and PI to determine proportions of necrotic and apoptotic
king antibody for 3 hours and then treated with gemcitabine during
ermined as in (A). (C) B16F10 cells were treated with 5 μM PH797804 and
s of necrotic and apoptotic cells were determined as in (A). Data are
itabine.
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tions of apoptotic and necrotic cells in co-cultured
PH797804 and gemcitabine-treated B16F10 cells were
increased (Figure 5C). A possible acting model for this
chemoresistance induction is depicted in Figure 6 and
illustrates that suppression of antitumor T-cell response
via the interaction between PD-1 on effector T cells and
induced PD-L1 on tumor cells may lead to this resis-
tance of drug treatment.
Discussion
Tumor immune surveillance has been shown to be es-
sential for tumor cell survival during tumor progression
and metastasis. One of the major molecular regulators
of tumor immune escape is PD-L1, which inhibits T
cell–mediated immune attack through binding to its
receptor PD-1 on tumor-specific T cells [28]. PD-L1 ex-
pression has been reported in several human malig-
nancies and has been linked to poorer prognosis and
increased resistance to anticancer therapies in many of
these malignancies [29]. Although several mechanisms,
such as PI3K and STAT3 signaling pathways via PTEN
inhibition, of PD-L1 regulation on tumor cells have been
reported [20,23,24], the cellular interactions between
tumor cells and tumor stromal cells responsible for
PD-L1 expression have remained unknown. Besides the
pathways already reported for PD-L1 regulation, this re-
port demonstrates for the first time that tumor cell sur-
face expression of PD-L1 is induced through direct
interaction with BM cells in the tumor microenviron-
ment and that this effect is p38 dependent.Figure 6 Model of PD-L1 induction on tumor cells by
CD11b-positive BM. BM cells adhere to the surface of tumor cells
through CD11b interaction with an unknown receptor on the tumor
cell surface. This interaction activates the p38 signaling pathway and
induces PD-L1 expression, both intracellular and on the tumor cell
surface. Overexpressed PD-L1 may play a role in metastasis, immune
evasion, and drug resistance.Over the last decade, the tumor microenvironment
has been a topic of great interest, with the goal of under-
standing the contribution of tumor stromal components
to regulation of tumor progression and metastasis [30].
BM-driven cells have been shown to have direct impact
on tumor progression and metastasis by regulating
angiogenesis, inflammation, and immune suppression.
Moreover, increased BM recruitment by tumors has
been associated with poor prognosis in clinical studies.
Better prognoses have been observed when tumor sites
are loaded with tumor-infiltrating lymphocytes (TILs) to
aid the immune system in the clearance of tumor cells.
However, PD-L1 positivity at tumor sites was also asso-
ciated to TILs with poor prognoses, as tumor cells might
exploit the PD-L1 expression to overcome antitumor im-
mune responses mediated by TILs [29,31]. This observa-
tion strongly suggests that the oncogenic drivers for
malignant transformation result in expression of the in-
ducible ligand PD-L1 as a generalizable principle of the
development of the malignant phenotype. Furthermore,
the components of the BM-derived tumor microenviron-
ment may be targeted and studied as a biomarker for
cancer metastasis [32]. However, a role for BM cells in
the regulation of PD-L1, a regulator of tumor immune
surveillance, had not been addressed and was the subject
of this study. This investigation of a putative role for BM
cells in regulation of PD-L1 expression on tumor cells
showed that cell surface PD-L1 expression was induced
in different tumor cells by co-culture with BM cells.
Furthermore, CD11b was critical for induction of PD-L1
expression by direct contact with BM. Additional in-
vestigations examined whether B16F10 cells expressed
ICAM-1, a known receptor for CD11b, and whether en-
gagement of the receptor was involved in PD-L1 expres-
sion on B16F10 cells during BM cell co-culture. ICAM-1
expression was detected on only ~25% of co-cultured
B16F10 cells, whereas more than 90% of these cells
expressed PD-L1 (Additional file 1: Figure S4). These re-
sults suggest that ICAM-1 was not the CD11b receptor
associated with induction of PD-L1 expression on tumor
cells during BM co-culture. The results presented in this
study, therefore, point to the possibility of an unknown
receptor on B16F10 tumor cells that bound BM CD11b
to trigger PD-L1 expression.
The findings that the p38 MAPK pathway was acti-
vated by communication between BM and B16F10
tumor cells and mediated PD-L1 expression on the
tumor cells are corroborated by the recent observation
that p38 activation is important for poly I:C–induced
PD-L1 expression in myeloid dendroid cells [33]. The
expression of PD-L1 has been associated with MAPK
signaling in other tumor types. The activation of Toll-
like receptor 4 signaling by lipopolysaccharide stimula-
tion induced PD-L1 expression in bladder cancer cells
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expression was found to be regulated by MEK/ERK sig-
naling in anaplastic large cell lymphoma and Hodgkin
lymphoma, and the ERK and p38 MAPK signaling path-
ways were suggested to be involved in the regulation of
PD-L1 in Hodgkin lymphoma cells [34]. Thus, this study
underlines the important role of the p38 pathway in
influencing PD-L1 expression and show, for the first time,
this mode of action in the tumor microenvironment.
Finally, that BM cells protected B16F10 cells from
gemcitabine treatment and this drug resistance was
blocked by PD-L1 neutralization in B16F10 cells, indi-
cating the significance of tumor cell surface PD-L1 in
drug resistance of tumor cells. This result is in line with
the anti-apoptotic role of cell surface PD-L1 in breast
cancer cells [35]. That study showed that cell surface
PD-L1 expression was downregulated by doxorubicin
treatment and that this effect was accompanied by up-
regulation of PD-L1 in the nucleus, suggesting the role
of cell surface PD-L1 in apoptosis. PD-L1 knockdown
using siRNA led to an increase in spontaneous apoptosis
as well as doxorubicin-induced apoptosis in these breast
cancer cells [35]. Additionally, gemcitabine treatment in
pancreas cancer patients showed no significant changes
in proportions of T and B-cells including CD86 and
CD80 APCs or CD4+, CD25+ T-cells [36]. Increased
population of CD14+ monocytes and CD11C+ dendritic
cells were also documented with gemcitabine treatment
in patients with advanced pancreatic cancer [37]. PD-L1
is a negative co-stimulatory molecule that is expressed
in many cancers, where it is believed to contribute to
the escape of tumors from immune recognition through
binding to its receptor, PD-1, on tumor-specific T cells
[38]. Upregulation of PD-L1 has been implicated in the
immune escape of several human malignancies and PD-
L1–positive status is linked to tumor metastasis, poor
survival, and increased risk of mortality in several hu-
man cancers [29]. Furthermore, blocking of PD-L1 or
PD-1 with monoclonal antibodies has been demon-
strated to trigger antitumor immune responses and en-
hance the effectiveness of anticancer immunotherapy
[39]. Targeting this molecule may therefore lead to a
major breakthrough in cancer treatment.
Conclusions
This study demonstrates that BM cells expressing
CD11b directly communicate with tumor cells and acti-
vate the p38 MAPK pathway (Figure 6). Tumor cell
surface PD-L1 is overexpressed through this cell-cell
contact in the tumor microenvironment, and this effect
is dependent on the p38 signaling pathway. Overex-
pression of PD-L1 increases drug resistance and protects
tumor cells from drug treatment. Further study of the
CD11b–p38–PD-L1 signaling axis may lead to deve-lopment of novel therapeutic targets for cancer. Further
investigation of the unknown CD11b-interacting protein
on tumor cells may be warranted.
Materials and methods
Cell culture and reagents
The cancer cell lines B16F10, DBT, 4 T1, LLC and LM8
were obtained from American Type Culture Collection
(Rockville, MD, USA). B16F10, DBT, 4 T1, LLC and
LM8 cells were cultured in Dulbecco modified Eagle
medium (DMEM)/F12 (Sigma) supplemented with 10%
fetal bovine serum and 10 U/ml penicillin and strepto-
mycin (Life Technologies, Grand Island, NY) at 37°C in
5% CO2. Cells were detached using 1 mM EDTA in
phosphate-buffered saline solution (PBS) and used for
further experiment. Antibodies used for western blotting
included PD-L1 (1:1000, R&D Systems, Minneapolis, MN),
p-p38 and β-actin (1:1000, Santa Cruz Biotechnology,
Dallas, TX). Antibodies for flow cytometry, including
pp38, pERK, pJNK pAKT, pmTOR, pp70-S6K, pSTAT1,
pSTAT3, pSTAT4 and pSTAT5, were purchased from Cell
Signaling Technology.
Animal ethics statement
The mice used in this study were maintained under
National Institutes of Health guidelines and euthanized
according to procedures approved by the Institutional
Animal Care and Use Committee of The University of
Texas MD Anderson Cancer Center.
Isolation of bone marrow cells from mouse bones
Six-to eight-week-old C57BL6, B−/−, CD11b−/−, CD28−/−,
Perforin−/−, and Rag2−/− mice obtained from the National
Cancer Institute or Jackson Laboratory (Bar Harbor, ME)
were used for this study. The bones were isolated from
the two rear legs of each mouse and washed with
phosphate-buffered saline solution (PBS) and DMEM/F12
medium. BM cells were flushed from both ends of the
bones into cell culture dishes by injecting DMEM/F12
medium via a 26-gauge needle and a 10-mL syringe. Col-
lected cells were subjected to lysis by red blood cell lysis
buffer for 4 minutes at room temperature. BM cell lysate
suspensions were passed through a 40-μM strainer and
washed twice with RPMI-1640 medium. The cells were re-
suspended in 4 mL of RPMI-1640 medium and combined
for co-culture with tumor cells.
In vitro bone marrow co-culture
Tumor cells were labeled with carboxyfluorescein diace-
tate succinimidyl ester (CFSE, Biolegend, San Diego,
CA) at a final concentration of 5 μM for 10 minutes at
37°C in darkness. After two washes with RPMI-1640
medium, the CFSE-labeled tumor cells were combined
with freshly isolated BM cells in cell culture plates at the
Noh et al. Cell Communication and Signaling  (2015) 13:14 Page 10 of 12ratio 1:10. After 48 hours of co-incubation, BM cells
were gently removed from the cell culture suspension
and adherent tumor cells were detached and collected
for further study. To investigate the manner of cell-cell
communication, BM cells were incubated on Thin-
CertTM cell culture inserts (Greiner Bio-One) with
translucent membranes and 0.4 μm pores, and B16F10
cells were cultured on the underside of the membrane
for 48 hrs. To test the role of the CD11b subpopulation
of BM cells, 2 μg/mL of anti-CD11b neutralization
antibody (BS Pharmingen, San Jose, CA) was added to
co-cultures. CD11b-positive cells were separated using
EasySepTM Mouse CD11b positive selection kit (Stemcell
technologies, Vancouver, Canada) and co-cultured with
B16F10 cells. To examine the activity of the p38 pathway,
p38 inhibitor PH797804 (Selleckchem, Houston, TX) was
added into the culture medium at a final concentration of
1 μM.Flow cytometry
CFSE-stained tumor cells harvested from co-cultures
were stained for PD-L1 expression. Briefly, tumor cells
were blocked for 10 minutes at room temperature with
FcR blocker in a 1:1000 dilution and then incubated
with anti-PD-L1 antibody (phycoerythrin [PE]-conju-
gated anti-mouse PD-L1, Biolegend) in a 1:50 dilution
in PBS + 2% serum for 15 minutes in the dark at room
temperature. To determine the activation of signaling,
tumor cells were fixed with 2% paraformaldehyde and
permeabilized with 100% methanol, followed by intra-
cellular staining with primary antibodies for p-p38,
pERK, pJNK, pAKT, pmTOR, pp70-S6K, pSTAT1,
pSTAT3, pSTAT4, and pSTAT5 and PE-conjugated
rabbit IgG secondary antibody (Santa Cruz Biotechnology).
Cells were analyzed on an Attune flow cytometer
(Life Technologies, Grand Island, NY) and the results
evaluated using FlowJo 10.0 software (Tree Star, Inc.,
Ashland, OR). CFSE-positive tumor cells were gated
for further analyses of the expression of PD-L1 and
intracellular cell signaling molecules. Gene expres-
sion was evaluated by Median Fluorescence Intensity
(MFI).Western Blot
Same amount of total proteins isolated using Radioimmu-
noprecipitation assay (RIPA) buffer were loaded onto 12%
sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE)
and transferred to nitrocellulose membranes using the
iBlot gel transfer device (Invitrogen, Grand Island, NY).
The membranes were blotted with anti-PD-L1- or aniti-p-
p38-primary antibody and HRP-conjugated secondary
antibody (Santa Cruz Biotechnology, Dallas, TX) to detect
the protein of interest.Quantitative Reverse transcription polymerase chain
reaction (qRT-PCR)
Total RNA was extracted from cells using Trizol (Invitrogen)
and quantitative reverse transcriptase PCR(qRT-PCR) was
performed as previously described [40] to measure the
levels of PD-L1. The levels of GAPDH mRNA were also
measured and used as the internal normalization control.
The forward and reverse primer sequences for the mouse
PD-L1 and GAPDH are 5′-ACAGCCAGGGCAAAA
CCA-3′ (forward), 5′-GGATGTGTTGCAGGCAGTT




For immunofluorescence imaging, the cells were cul-
tured in chamber slides (Fisher scientific) and performed
as previously described [41] to detect PD-L1 expression.
After fixation using 4% paraformaldehyde (Fisher scien-
tific), cells were washed in PBS (pH 7.4) and blocked in
blocking buffer (1% FBS in PBS with 0.01% NP40) for an
hour. Later, cells were incubated with PD-L1 antibody
(1:1000 in blocking buffer) overnight in cold room. Cells
were then rinsed in PBS and stained with Alexa Fluor-
555 secondary antibodies (Invitrogen) (1:250) for PD-L1
staining (species: rabbit). For nuclei staining, DRAQ5
(CellSignaling) (1:1000) was incorporated along with sec-
ondary antibody for 60 min. The cells were then washed
with PBS (pH 7.4) three times for 15 min each and
mounted in Slow fade antifade (Invitrogen). For confocal
analysis, images were acquired in 8 bits with the Zeiss
LSM 510 confocal microscope using LSM 5 3.2 image
capture and analysis software (Zeiss). A 63× water-
immersion objective lens (NA, 1.0) was used with digital
zoom for image capture. All images were acquired by
the same operator using the same intensity and photo
detector gain in order to allow quantitative comparisons
of relative levels of immunoreactivity between different
samples.
Annexin V and propidium iodide staining
B16F10 cells were co-cultured with fresh BM cells with
or without 1 μM gemcitabine for 48 hours. To test the
role of PD-L1 in cell response to the drug, B16F10 cells
were pre-incubated with 2 μg/mL of PD-L1 blocking
antibody (eBioscience, San Diego, CA) for 2 hours be-
fore co-culture with freshly isolated BM cells and treat-
ment with gemcitabine (1 μM). To test cell viability,
B16F10 cells were treated with 5 μM PH797804 during
co-culture. To examine the role of p38 in the PD-L1 me-
diated drug resistance, B16F10 cells were treated with
5 μM PH797804 and 100 μM gemcitabine. After
48 hours of co-culture, single-cell suspensions were
prepared with cold PBS buffer. After two washes, cells
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annexin V binding buffer (Biolegend). Aliquots (100 μL)
of the cell suspension were incubated with 5 μL of
Pacific blue–conjugated annexin V (Biolegend) and 5 μL
of propidium iodide (PI) solution (Biotium, Hayward,
CA) for 15 minutes at room temperature in darkness.
After staining, 400 μL of annexin binding buffer was
added to the cells, which were immediately analyzed by
flow cytometry.
Statistical analysis
Results are expressed as mean ± standard deviation. Data
were analyzed with GraphPad software (GraphPad Soft-
ware, Inc., La Jolla, CA) using an unpaired two-tailed Stu-
dent t-test to detect the significance of differences between
groups. P <0.05 was considered statistically significant.
Additional file
Additional file 1: Bone Marrow cells induce PD-L1 expression on
tumor cells. (A) LM8, (B) 4 T1, and (C) LLC tumor cell surface PD-L1
expression after co-culture with BM cells for 48 hrs. Cells were stained
with isotype control or PE-PD-L1 antibody. PD-L1 expression level was
determined using flow cytometry. Data are presented as mean ± standard
error (n = 3). *, P < 0.05 versus B16F10 alone, student t test. S2. Direct
interaction between BM and tumor cells is required for PD-L1 expression.
DBT brain tumor cells were co-cultured with BM cells together or
separately using transwell membrane. Cells were stained with isotype
control or PE-PD-L1 antibodies, followed flow cytometry analysis. (A) Bar
graph, Data are presented as mean ± standard error (n = 3). (B) Histogram
*, P < 0.05 versus B16F10 alone, student t test. S3. pStat3 was not activated
by BM co-culture in B16F10 cells. B16F10 cells co-cultured with BM cells
were subjected to lysis, and cell lysates were subjected to immunoblotting
to detect pStat3 levels. β-actin was used as a loading control. S4. PD-L1
induction is not correlated with ICMA-1 on tumor cells. B16F10 tumor cells
were co-cultured with BM cells for 2 days. Cells were stained with isotype
control, PE/Cy7-PD-L1 or PE-ICAM-1 antibodies, followed flow cytometry
analysis. Results are representative of three independent experiments.
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